Sinco Pharmaceuticals Holdings Limited (Sinco Pharma) secured unanimous shareholder support at its Annual General Meeting (AGM) on 15 May 2026, with every resolution receiving 1.05 billion votes in favour, representing 100.00% of votes cast.
Financial statements and dividend • Shareholders adopted the audited consolidated results for the year ended 31 December 2025. • A final dividend of HK0.167 cents per share—totalling HK$3.40 million—was approved.
Board composition and auditor • Independent non-executive directors Mr Wang Qing, Mr Bai Zhizhong and Mr Lau Ying Kit were each re-elected. • The Board was authorised to determine directors’ remuneration. • Rongcheng (Hong Kong) CPA Limited was re-appointed as external auditor for the 2026 financial year.
Capital mandates Based on the 2.03 billion shares in issue on the AGM date: • Issuance mandate: Directors may allot and deal with up to 20% of issued shares—approximately 406.58 million shares. • Share buy-back mandate: The Company may repurchase up to 10% of issued shares—around 203.29 million shares. • An extension mandate allows the issuance limit to be increased by the number of shares actually repurchased.
Participation and governance • Valid voting rights attached to 1.05 billion shares were exercised at the meeting, implying a turnout of about 51.66% of the total issued share capital. • Computershare Hong Kong Investor Services Limited acted as the meeting scrutineer, and all directors were in attendance.
All ordinary resolutions required a simple majority and were duly passed, reinforcing shareholder endorsement of Sinco Pharma’s 2025 performance, board composition and capital management flexibility.
Comments